Tresiba (Insulin Degludec) Compounding Legal Status: What Women Need to Know

What Is Tresiba and Why Does Its Legal Status Matter to You?

Tresiba is Novo Nordisk's brand name for insulin degludec, an ultra-long-acting basal insulin with a half-life of roughly 25 hours, giving it a duration of action exceeding 42 hours in most adults. That flat, predictable profile has made it popular for people who need stable overnight coverage without peaking.

The legal status question matters because a wave of telehealth compounding pharmacies began marketing compounded versions of GLP-1 drugs during shortage periods, and some patients reasonably wonder whether the same applies to insulin degludec. The short answer: it does not.

What "Compounding Legal Status" Actually Means

Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act, a drug may be compounded legally only when FDA places it on an official shortage list or, in limited cases, when a patient cannot use the commercially available product for a documented clinical reason. FDA maintains the Drug Shortage Database in real time.

Insulin degludec has not appeared on that database as a shortage product as of this article's review date. That means compounding pharmacies, regardless of their 503A or 503B designation, have no legal basis to produce and sell it at scale.

Why This Matters Differently for Women

Women with type 1 or type 2 diabetes, PCOS-related insulin resistance, or diabetes diagnosed during pregnancy face unique treatment continuity pressures. If you were told a compounded product is "the same" as Tresiba, be aware that compounded versions lack the FDA's required bioequivalence testing, have no guaranteed sterility standards equivalent to the approved product, and carry no post-market surveillance obligation.

FDA Approval History of Tresiba

Tresiba received FDA approval on September 25, 2015, for adults with type 1 and type 2 diabetes. The approval covered two concentrations: U-100 (100 units/mL) and U-200 (200 units/mL), both delivered via the FlexTouch prefilled pen. A pediatric indication for patients one year and older was added in subsequent labeling updates.

The Drugs@FDA Record

The full regulatory file, including all labeling revisions, risk evaluation documents, and the clinical pharmacology review, is publicly searchable at Drugs@FDA under NDA 203314. The most recent label revision was in 2019 and remains the controlling document for prescribers and pharmacists.

EMA Parallel Approval

The European Medicines Agency approved insulin degludec in 2012 under the brand name Tresiba, three years before U.S. Approval. The EMA EPAR summary is publicly available and contains pharmacovigilance data from European post-market use, including pregnancy registry entries, that supplements the thinner U.S. Dataset.

What the Tresiba Label Says

The current FDA-approved label contains several points that are especially relevant to women.

Dosing

Starting doses for insulin-naive adults with type 2 diabetes are 10 units once daily. For patients transitioning from another basal insulin, the conversion is unit-for-unit for most long-acting insulins. The label is explicit that dose adjustments must be based on metabolic need and fasting glucose, not on a fixed schedule, which matters for women whose insulin requirements fluctuate with the menstrual cycle (see the physiology section below).

Contraindications

The label lists only two contraindications: hypersensitivity to insulin degludec or any of its excipients, and episodes of hypoglycemia. There is no blanket contraindication in pregnancy, but the label's pregnancy section uses cautionary language that every woman of reproductive age should read before starting this insulin.

Black Box Warning

Tresiba carries no black box warning specific to the drug itself. The labeling does carry the class-wide caution about hypoglycemia as the most common adverse effect of all insulins, with severe hypoglycemia capable of causing seizures, loss of consciousness, and death.

Drug Interactions Relevant to Women

Several drug classes used disproportionately by women affect insulin requirements. Oral contraceptives, including combined estrogen-progestin pills, can increase insulin resistance and raise fasting glucose. Thyroid hormone replacement therapy, used by approximately twice as many women as men, alters glucose metabolism and may require Tresiba dose titration after any thyroid dose change. The label acknowledges hormone therapies as a class that may increase insulin requirements but does not provide women-specific dose-adjustment guidance, a gap that clinical practice has had to fill with individualized monitoring.

Sex-Specific Physiology: How Being a Woman Changes Your Tresiba Dose

Insulin requirements in women are not static. They shift in predictable patterns tied to the hormonal events of your reproductive life, and understanding those patterns helps you have a better conversation with your care team about titration.

During the Menstrual Cycle

In the luteal phase (roughly days 15 to 28), rising progesterone increases peripheral insulin resistance. Many women with type 1 diabetes report needing 10 to 20 percent more basal insulin in the week before menstruation, with requirements dropping sharply at the onset of flow. Tresiba's long half-life is both an advantage and a challenge here: the stable profile prevents overnight peaks but also means adjustments take approximately three days to reach a new steady state, so premenstrual dose increases must be planned in advance rather than made reactively.

In Perimenopause

The hormonal fluctuations of perimenopause, characterized by erratic estrogen surges and drops over a transition that averages four to eight years, create unpredictable changes in insulin sensitivity. Women with pre-existing type 1 or type 2 diabetes frequently report worsening glycemic control during perimenopause even without changes to diet or physical activity. The Menopause Society's 2023 position statement on hormone therapy notes that menopausal hormone therapy (MHT) with estradiol can improve insulin sensitivity, which may necessitate downward Tresiba titration in women who start MHT after menopause.

In Postmenopause

After menopause, the loss of estrogen's insulin-sensitizing effect and the shift toward central adiposity both tend to increase basal insulin requirements over time. Women in this life stage may also be managing thyroid disease, osteoporosis medications, and cardiovascular risk simultaneously, all of which can interact with glycemic control.

In PCOS

PCOS affects approximately 8 to 13 percent of women of reproductive age and is defined in large part by insulin resistance regardless of body weight. Basal insulin like Tresiba is not a first-line treatment for PCOS-related insulin resistance (metformin and lifestyle modification hold that position), but women with PCOS who also have type 1 diabetes or advanced type 2 diabetes may use Tresiba. In that context, the hyperandrogenism of PCOS can compound insulin resistance, and dose requirements may be higher than those seen in women without PCOS at a comparable BMI.

Tresiba Safety: Key Trial Data and Post-Market Evidence

The DEVOTE Trial

The most definitive cardiovascular safety trial for Tresiba is DEVOTE (NEJM 2017), a double-blind, treat-to-target trial comparing insulin degludec to insulin glargine U-100 in 7,637 adults with type 2 diabetes and high cardiovascular risk. Tresiba was non-inferior to glargine on the primary MACE endpoint (cardiovascular death, non-fatal MI, or non-fatal stroke; hazard ratio 0.91, 95% CI 0.78 to 1.06). Severe hypoglycemia occurred in 40 percent fewer patients on degludec than on glargine (rate ratio 0.60, 95% CI 0.48 to 0.76).

A critical gap: women comprised only 37 percent of the DEVOTE population. The trial was not powered to detect sex-specific differences in MACE outcomes or hypoglycemia rates. Subgroup analyses did not show a statistically significant sex interaction, but the confidence intervals in female-only subgroups were wide enough to preclude definitive conclusions. This is the kind of honest limitation you deserve to know.

FDA Sentinel Post-Market Surveillance

FDA's Sentinel System, the nation's active post-market surveillance network covering over 300 million patient-lives, has included insulin degludec in ongoing pharmacovigilance since its U.S. Approval. No new safety signals specific to women have been formally published as a Sentinel query result, but the surveillance remains active, particularly for hypoglycemia-related hospitalizations.

Hypoglycemia Risk in Women

Women experience hypoglycemia differently than men. Research published in Diabetes Care suggests that women with type 1 diabetes have blunted hormonal counter-regulatory responses to hypoglycemia compared with men, meaning the body's alarm signals (sweating, tremor, palpitations) may be weaker or delayed. This makes the hypoglycemia-sparing advantage of Tresiba over glargine, demonstrated in DEVOTE, especially meaningful for women.

Pregnancy, Lactation, and Contraception

This section is required reading if you are pregnant, planning pregnancy, or breastfeeding.

Pregnancy Safety

Tresiba does not carry a legacy FDA pregnancy letter category because it was approved after the FDA's 2015 Pregnancy and Lactation Labeling Rule (PLLR) replaced the A/B/C/D/X system. The current label states that animal reproduction studies showed no adverse effects on fetal development at doses up to 10 times the human dose, but human data specific to insulin degludec in pregnancy are limited.

Poorly controlled diabetes in pregnancy carries well-documented risks: congenital anomalies, macrosomia, preeclampsia, and stillbirth rates that are two to five times higher than background risk. The ACOG Practice Bulletin on Pregestational Diabetes Mellitus recommends that insulin regimens in pregnancy prioritize established safety profiles; NPH insulin and insulin detemir have more human gestational data than insulin degludec. If you become pregnant while using Tresiba, your care team may consider switching to detemir, for which a dedicated pregnancy trial exists.

Insulin requirements change dramatically across pregnancy: they typically decrease in the first trimester, rise sharply in the second and third trimesters as placental hormones increase insulin resistance, and then drop precipitously at delivery. Tresiba's three-day titration lag requires careful forward planning during these transitions.

Lactation

Insulin is a large peptide molecule. Insulin degludec does transfer into breast milk, but peptide insulins are degraded in the infant gastrointestinal tract and are not expected to cause clinical effects in a nursing infant. The Tresiba label considers use during breastfeeding acceptable with monitoring. Breastfeeding itself lowers maternal blood glucose and may reduce basal insulin requirements by 10 to 25 percent in the early postpartum period; your dose should be reassessed at each feeding stage transition.

Contraception Note

Tresiba is not a teratogen in the classic sense (it is not contraindicated the way methotrexate or isotretinoin are), but uncontrolled diabetes at conception significantly increases the risk of fetal harm. The American Diabetes Association's Standards of Care 2024 recommend that women with diabetes discuss preconception planning with their diabetes care team before attempting pregnancy, ensure HbA1c is below 6.5 percent if safely achievable before conception, and use reliable contraception until glycemic goals are met. If you are using Tresiba and are sexually active with potential for pregnancy, talk to your provider about that HbA1c target before discontinuing contraception.

Who This Is Right For, and Who Should Be Cautious

Women Who May Benefit Most from Tresiba

• Women with type 1 or type 2 diabetes who experience significant overnight hypoglycemia on glargine or detemir, given DEVOTE's 40 percent lower severe hypoglycemia rate
• Women with highly variable schedules who cannot inject basal insulin at the same time each day (the label permits injection at any time of day, with a minimum eight-hour window between doses)
• Postmenopausal women with type 2 diabetes and established cardiovascular disease, given the MACE non-inferiority data in DEVOTE
• Women on menopausal hormone therapy who need a stable basal platform while other insulin-sensitizing effects are being optimized

Women Who Need Extra Monitoring or Alternative Consideration

• Pregnant women: consider switching to detemir, which has dedicated gestational trial data, unless your care team has a specific clinical rationale for continuing degludec
• Women with severe renal impairment: the label notes that pharmacokinetics are altered and hypoglycemia risk is higher
• Women newly starting insulin who are also initiating oral contraceptives: the combined insulin-sensitizing effect of estrogen and the resistance-inducing effect of progestin can create volatile glucose patterns in the first two to three months
• Women with PCOS who are not yet on a GLP-1 or metformin and whose primary problem is insulin resistance rather than absolute insulin deficiency: basal insulin amplifies hyperinsulinemia rather than addressing its root cause

The Compounding Question: A Closer Look

Why Compounding Became Visible

The 2022 to 2024 shortages of semaglutide and tirzepatide prompted FDA to list those drugs on the shortage database, opening a legal window for 503A and 503B compounders. That window attracted substantial commercial activity. Some compounding pharmacies, and some telehealth platforms sourcing from them, began marketing a range of injectable drugs under a general "compounded hormone or peptide" framing that patients reasonably found confusing when applied to insulin.

The Specific Legal Bar for Insulin Degludec

Insulin as a drug class has additional FDA oversight beyond standard compounding rules because insulin was previously regulated as a biologic and has unique sterility requirements. Insulin degludec specifically requires a hexamer-dihexamer-multihexamer self-association mechanism at the subcutaneous depot that produces its ultra-long half-life. Reproducing that molecular behavior in a compounding pharmacy setting, without bioequivalence testing, is not scientifically equivalent to the approved product.

What to Do If You Were Offered Compounded Tresiba

If a pharmacy or telehealth platform offered you compounded insulin degludec, you can file a report with FDA MedWatch and check the pharmacy's 503B registration status at FDA's registered outsourcing facilities list. Using an unregulated insulin product carries real risk: concentration errors in compounded insulin have caused both severe hypoglycemia and hyperglycemic crises.

A Practical Note on Cost and Access

One reason patients ask about compounding is cost. Tresiba's list price is approximately $315 to $380 per pen box (five pens, 300 units each). Novo Nordisk's My$99Insulin program caps the cost at $99 per month for patients who qualify. The federal Inflation Reduction Act insulin price cap of $35 per month applies to Medicare Part D enrollees as of 2023. If cost is driving the question, these are the legitimate access pathways to explore rather than unregulated compounding.